

Role of Prophylactic Thyroid Neck Dissection in Papillary Thyroid Cancer

Hisham Sameer Alhathloul¹, Mohammed Ahmed Almasabi²,
Abdulghani Mohammad Lodhi³, Atheer Majed Alghamdi⁴

1-King Faisal Unilversity,2-King Khalid University, 3-King Abdulaziz University,4-Almaarefa Colleges for Science and Technology

ABSTRACT

Background: the utility and efficacy of prophylactic central neck dissection with total thyroidectomy for treatment of differentiated thyroid cancers has been debated in the literature over the past few decades. Proponents of prophylactic central neck dissection support its routine use with the notion that it reduces local recurrence, increases accuracy in TNM staging and reduces surgical morbidity associated with reoperation. Conversely, those against the use of routine prophylactic central neck dissection argue there was no clear evidence which showed a reduction in recurrence or added benefit to survival, while the procedure increased the risk for complications and morbidity. This article discussed the role of prophylactic central neck dissection in the setting of thyroid cancer and reviewed recently published literatures to evaluate efficacy and safety of this procedure. The papillary thyroid carcinoma (PTC) is the most common disorder with favorable prognosis around the world. PTC has 90% survival rate, but the most important challenge was the lymph node metastases that would result in disease recurrence. There is a debate about the utility of prophylactic central neck dissection in the area of PTC. The available studies for performing PCND showed a difficulty in predicting its outcomes, but PCND could provide potential reduction in the recurrence rates and risks of performing another surgery in the neck. This review discussed the PCND advantages compared to its long term outcomes and morbidity.

Keywords: papillary thyroid carcinoma (PTC), prophylactic central neck dissection (pCND), metastases, lymph node.

INTRODUCTION

Differentiated thyroid cancer (DTC) is a major and most popular endocrine malignancy with a high prevalence among other types of cancers around the world ⁽¹⁾. The papillary thyroid carcinoma (PTC) represents about 85% of thyroid cancers and about 35% of PTC patients had macrometastatic cervical lymph node metastases^(2,3).

Other studies showed an average of 60 % of PTC patients developed cervical lymph node metastases in the central compartment ⁽⁴⁻⁶⁾. In spite high mortality rates of cancer, the 5-10 years survival rate of PTC patients was above 90% ⁽⁷⁾.

Total thyroidectomy (TT) surgery was the main corner stone in treatment of PTC, but about 15% of patients underwent total thyroidectomy would develop nodular recurrence, thus nodal metastases is an ideal prognostic factor for disease recurrence ^(8,9).

The addition of prophylactic central neck dissection to the total thyroidectomy is a treatment of choice for preventing neck metastases and recurrence of nodules ⁽¹⁰⁻¹²⁾. But this is still a debate in DTC patients with clinically node-negative

because of there is a lack in the studies concerning this issue ^(6,13).

Also, the American Thyroid Association (ATA) Guidelines for DTC patients recommended the addition of prophylactic central-compartment neck dissection (PCND) in PTC patients with clinically uncomplicated central neck lymph nodes (cN0) or clinically complicated lateral neck nodes (cN1b)⁽¹⁴⁾.

Definition of central Neck Dissection (CND)

Till now there is an inconsistent definition of what CND is and what it contains (15, 16). The ATA described the central compartment as a lymph node compartment bounded from the superior part by the hyoid bone, from the inferior part by the innominate artery and from the lateral part by the common carotid arteries^(15,16).

Also, it is bounded from the anterior and posterior parts by the superficial and deep layer of the deep cervical fascia. Also, as for the nodal groups, it included the pre- and para-tracheal, as well as prelaryngeal lymph node basin ^(17,18).

Significance of PCND

The central compartment is the most common site for nodal metastases in PTC patients, thus removing the lymph nodes is supposed to reduce the recurrence rate^(14, 19).

Effects on Survival

The survival rate of PTC patients was greater than 90% for more than 10 years, thus the impacts of PCND was difficult to be evaluated due to the long term of survival and the length of follow up required for the study. However, a retrospective long term study showed that the survival rate after performing PCND with TT was significantly higher (98%) when compared to 92.5% in those patients who underwent TT alone thus PCND is suggested to increase the survival rate⁽²⁰⁾.

Effects on Local Recurrence

The PCND was supposed to eliminate the nodal recurrence in the central compartment for PTC patients by removing the metastatic positions and histological analysis of the suspected lymph nodes for identification of metastases^(14, 21). Also, a significant reduction in the nodal recurrence by 35% was observed by **Lang et al.**,⁽¹⁹⁾ when performing TT associated with PCND in comparison with TT alone. Another study proposed the same results, but for short term survival rate (5 years) and indicated the impact of PCND in reducing the rates of recurrence⁽¹³⁾. However, after addition of radioactive iodine ablation (RAI) therapy, the reduction in the recurrence showed no significant difference either between TT with PCND group or TT alone group⁽²⁰⁾.

Other studies also showed that there was no significant difference in recurrence rate in TT group combined with PCND than TT alone group^(5, 22-24).

Outcomes of PCND

Many studies referred to the complications of PCND during performing TT^(25, 26). The risks of hematoma, hypoparathyroidism and recurrence of laryngeal nerve injury are major complications of PCND like those consequences of total thyroidectomy with rates less than 1-2% suggesting that PCND is of no value⁽²⁷⁾. Also, other studies showed that the risks of temporary hypoparathyroidism are potentially increased after addition of PCND to TT^(5, 19, 28, 29). However, the complications of the surgery could be minimized with a specialist to avoid the risks of division and

manipulations of parathyroid vasculature during dissection^(26, 30). In addition, the bilateral dissection was significantly associated with higher complications rates than ipsilateral type associated with a higher complication rate including permanent hypoparathyroidism^(31, 32).

Other risks for PCND are the high morbidity rates and recurrent laryngeal nerve palsy which would result in threatening of life as well as the paralysis of the vocal cord⁽³³⁾.

The complications of PCND could be prevented or lessened by taking care of the operation procedures and having good visualization of recurrent laryngeal nerve during the dissection. Also, the closure should be carried out using sharp dissection instead of electrocautery that would result in spread of injury and thermal⁽³⁴⁾.

Also, a study showed that the utility of prophylactic PCND for PTC patients with no value on recurrence or other complications of TT⁽³⁵⁾.

In addition, the use of PCND was supposed to be restricted to high risk patients with an experienced surgeon because its efficiency is inadequate to compensate its complications⁽³⁶⁾.

CONCLUSION

There is still a debate surrounding the issue of adding PCND to TT for clinically uncomplicated central neck lymph nodes (cN0) or clinically complicated lateral neck nodes (cN1b). Also, the ATA presented many contradictions for emerging PCND in routine TT surgery for PTC patients, but its recommendations is based on the risks and stages of tumor. Many studies declared that there was a tendency toward using PCND for decreasing the risks of recurrence than in patients without PCND. Thus, PCND could be used for decreasing the recurrence rate, identification and removing of metastases. Also, using an ipsilateral unilateral PCND would result in decreasing the disease recurrence and balance the surgical morbidity. On the other hand, the advantages of PCND couldn't compensate its outcomes in other studies. More prospective studies with large population size are needed for assessing the long term benefits of PCND.

REFERENCES

1. Pellegriti G, Frasca F, Regalbuto C, Squatrito S and Vigneri R (2013): Worldwide increasing incidence of thyroid cancer: update on epidemiology

- and risk factors. *Journal of Cancer Epidemiology*, 2013: 965-970.
2. **Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R *et al.* (2003):** Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. *Surgery*, 134: 946-954.
 3. **Clark OH (2011):** Thyroid cancer and lymph node metastases. *J. Surg. Oncol.*, 103: 615-618.
 4. **Moo TA, McGill J, Allendorf J, Lee J, Fahey T, 3rd and Zarnegar R (2010):** Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. *World Journal of Surgery*, 34: 1187-1191.
 5. **Shan CX, Zhang W, Jiang DZ, Zheng XM, Liu S and Qiu M (2012):** Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. *The Laryngoscope*, 122: 797-804.
 6. **Li XY, Zhang B and Lin YS (2017):**The interpretation of 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. *Chinese Journal of Head and Neck Surgery*, 52: 309-315.
 7. **Lang BH, Lo CY, Chan WF, Lam KY and Wan KY (2007):** Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. *Ann. Surg. Oncol.*, 14: 730-738.
 8. **Wada N, Suganuma N, Nakayama H, Masudo K, Rino Y, Masuda M *et al.* (2007):** Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes. *Arch Surg.*, 392: 417-422.
 9. **Wu MH, Shen WT, Gosnell J and Duh QY (2015):** Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer. *Head Neck*, 37: 1336-1343.
 10. **Shindo M, Wu JC, Park EE and Tanzella F (2006):** The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. *Archives of Otolaryngology Head and Neck Surgery*, 132: 650-654.
 11. **Roh JL, Park JY, Rha KS and Park CI (2007):** Is central neck dissection necessary for the treatment of lateral cervical nodal recurrence of papillary thyroid carcinoma? *Head and Neck*, 29: 901-906.
 12. **Na'ara S, Amit M, Fridman E and Gil Z (2016):** Contemporary management of recurrent nodal disease in differentiated thyroid carcinoma. *Rambam Maimonides Medical Journal*, 7: 1-7.
 13. **Carling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, Kim LT *et al.* (2012):** American thyroid association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. *Journal of the American Thyroid Association*, 22: 237-244.
 14. **Haugen BR (2017):** American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? *Cancer*, 123: 372-381.
 15. **Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ *et al.* (2009):** Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. *Journal of the American Thyroid Association*, 19: 1153-1158.
 16. **Orloff L and Kuppersmith RB (2010):** American thyroid association's central neck dissection terminology and classification for thyroid cancer consensus statement. *Journal of American Academy of Otolaryngology Head and Neck Surgery*, 142: 4-5.
 17. **Hall CM, Snyder SK, Maldonado YM and Lairmore TC (2016):** Routine central lymph node dissection with total thyroidectomy for papillary thyroid cancer potentially minimizes level VI recurrence. *Surgery*, 160: 1049-1058.
 18. **White ML, Doherty GM (2007):** Level VI lymph node dissection for papillary thyroid cancer. *Minerva Chirurgica*, 62: 383-393.
 19. **Lang BH, Ng SH, Lau LL, Cowling BJ, Wong KP and Wan KY (2013):** A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy. *Journal of the American Thyroid Association*, 23: 1087-1098.
 20. **Barczynski M, Konturek A, Stopa M and Nowak W (2013):** Prophylactic central neck dissection for papillary thyroid cancer. *The British Journal of Surgery*, 100: 410-418.
 21. **Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS *et al.* (2008):** Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. *Surgery*, 144: 980-987.
 22. **Wang TS, Cheung K, Farrokhyar F, Roman SA and Sosa JA (2013):** A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. *Ann. Surg. Oncol.*, 20: 3477-3483.
 23. **Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P *et al.* (2015):** Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. *The Journal of Clinical Endocrinology and Metabolism*, 100: 1316-1324.
 24. **Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI and Clayman GL (2012):** In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional

- control and survival. *Journal of the American Thyroid Association*, 22: 347-355.
- 25.Zanocco K, Elaraj D and Sturgeon C (2013):** Routine prophylactic central neck dissection for low-risk papillary thyroid cancer: a cost-effectiveness analysis. *Surgery*, 154: 1148-1155.
- 26.Barczynski M, Konturek A, Stopa M and Nowak W (2014):** Nodal recurrence in the lateral neck after total thyroidectomy with prophylactic central neck dissection for papillary thyroid cancer. *Arch Surg.*, 399: 237-244.
- 27.Mazzaferrri EL, Doherty GM and Steward DL (2009):** The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. *Journal of the American Thyroid Association*, 19: 683-689.
- 28.Chisholm EJ, Kulinskaya E and Tolley NS (2009):** Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. *The Laryngoscope*, 119: 1135-1139.
- 29.Popadich A, Levin O, Lee JC, Smooke-Praw S, Ro K, Fazel M et al. (2011):** A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. *Surgery*, 150: 1048-1057.
- 30.Gyorki DE, Untch B, Tuttle RM and Shaha AR (2013):** Prophylactic central neck dissection in differentiated thyroid cancer: an assessment of the evidence. *Ann. Surg. Oncol.*, 20: 2285-2289.
- 31.Giordano D, Valcavi R, Thompson GB, Pedroni C, Renna L, Gradoni P et al. (2012):** Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. *Journal of the American Thyroid Association*, 22: 911-917.
- 32.Yoo HS, Shin MC, Ji YB, Song CM, Lee SH and Tae K (2017):** Optimal extent of prophylactic central neck dissection for papillary thyroid carcinoma: Comparison of unilateral versus bilateral central neck dissection. *Asian Journal of Surgery*. Available at: <http://dx.doi.org/10.1016/j.asjsur.2017.03.002>.
- 33.Kaplan EL, Salti GI, Roncella M, Fulton Nand Kadowaki M (2009):** History of the recurrent laryngeal nerve: from Galen to Lahey. *World Journal of Surgery*, 33: 386-393.
- 34.Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S and Delbridge L (2006):** Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. *Surgery*, 140: 1000-1005.
- 35.Lee DY, Oh KH, Cho J-G, Kwon S-Y, Woo J-S, Baek S-K et al. (2015):** The benefits and risks of prophylactic central neck dissection for papillary thyroid carcinoma: prospective cohort study. *International Journal of Endocrinology*, 215: 571480.
- 36.Hennessy M and Goldenberg D (2016):** The role of prophylactic central neck dissection in the treatment of differentiated thyroid cancer. *Rambam Maimonides Medical Journal*, 7: 7-15.